Structures by: Byrn S. R.
Total: 21
3-Benzyl-6-bromo-2-methoxyquinoline
C17H14BrNO
Acta Crystallographica Section C (2020) 76, 11
a=4.3606(6)Å b=10.820(2)Å c=29.886(11)Å
α=90° β=90° γ=90°
Bedaquline
C32H31BrN2O2
Acta Crystallographica Section C (2020) 76, 11
a=11.1584(8)Å b=13.6425(14)Å c=36.061(4)Å
α=90° β=90° γ=90°
Bedaqulinium benzoate acetonitrile 0.742-solvate monohydrate
C32H32BrN2O2,C7H5O2,0.742(C2H3N),H2O
Acta Crystallographica Section C (2020) 76, 11
a=12.8661(8)Å b=8.0386(5)Å c=17.4704(10)Å
α=90° β=101.093(3)° γ=90°
Bedaqulinium benzoate 1.166-hydrate
C32H32BrN2O2,C7H5O2,1.166(H2O)
Acta Crystallographica Section C (2020) 76, 11
a=12.6384(5)Å b=7.9259(3)Å c=17.5249(8)Å
α=90° β=99.8450(17)° γ=90°
Bedaqulinium 3-carboxyprop-2-enoate
C32H32BrN2O2,C4H3O4
Acta Crystallographica Section C (2020) 76, 11
a=16.4556(6)Å b=10.3205(3)Å c=20.1636(8)Å
α=90° β=109.1832(15)° γ=90°
<i>N</i>-{4-(3-Chloro-4-fluoroanilino)-7-[(tetrahydrofuran-3-yl)oxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide--acetonitrile--water (2/1/8)
2(C24H25ClFN5O3),0.5(C2H3N),4(H2O)
Acta Crystallographica Section E (2017) 73, 3 417-422
a=26.2427(4)Å b=26.2427(4)Å c=15.1639(3)Å
α=90° β=90° γ=90°
?
C27H48O6
Acta Crystallographica Section C (1996) 52, 10 2500-2502
a=25.483(4)Å b=8.0133(19)Å c=15.339(4)Å
α=90.00° β=121.581(14)° γ=90.00°
Sodium 3α,7α,12α-Trihydroxy-5β-cholan-24-oate Methanolate
C25H43NaO6
Acta Crystallographica Section C (1996) 52, 10 2495-2499
a=7.793(6)Å b=15.720(9)Å c=20.514(12)Å
α=90.00° β=90.00° γ=90.00°
Sodium 3α,7α,12α-Trihydroxy-5β-cholan-24-oate 2-Propanolate
C27H47NaO6
Acta Crystallographica Section C (1996) 52, 10 2495-2499
a=10.466(2)Å b=7.6364(19)Å c=17.197(2)Å
α=90.00° β=90.370(12)° γ=90.00°
3-(4-Nitroanilino)cyclopent-2-en-1-one
C11H10N2O3
Acta Crystallographica Section C (1997) 53, 11 1717-1719
a=8.2725(7)Å b=13.2730(10)Å c=9.5548(7)Å
α=90° β=97.510(6)° γ=90°
C15H11Cl1N2O3,C1H1Cl3
C15H11Cl1N2O3,C1H1Cl3
Acta Crystallographica Section C (1993) 49, 5 914-916
a=7.3490(10)Å b=10.613(2)Å c=11.721(2)Å
α=84.420(10)° β=79.420(10)° γ=83.230(10)°
3α,7α,12α-Trihydroxy-5β-cholan-24-amide Dihydrate
C24H41N1O4,2H2O1
Acta Crystallographica Section C (1997) 53, 4 480-482
a=10.3344(7)Å b=10.8162(7)Å c=11.3620(7)Å
α=90.00° β=108.730(6)° γ=90.00°
[8S-[7[R*(R*)],8R*]]-7-[2-[[1-(ethoxycarbonyl)-3- phenylpropyl]-amino]-1-oxopropyl]-1,4-dithia-7- azaspiro[4.4]nonane-8-carboxylic acid hydrochloride
C22H31N2O5S2,Cl1,H2O1
Acta Crystallographica Section C (1997) 53, 12 1917-1919
a=10.5075(15)Å b=10.6251(15)Å c=23.407(3)Å
α=90.00° β=90.00° γ=90.00°
N-methyl-3α,7α,12α-Trihydroxy-5β-cholan-24-amide Quarterhydrate
C25H43.5NO4.25
Acta Crystallographica Section C (1997) 53, 3 334-339
a=14.0117(11)Å b=8.0111(5)Å c=21.6959(11)Å
α=90.00° β=99.123(5)° γ=90.00°
N-methyl-3α,7α,12α-Trihydroxy-5β-cholan-24-amide Sesquihydrate
C25H46NO5.5
Acta Crystallographica Section C (1997) 53, 3 334-339
a=16.8089(9)Å b=38.7649(10)Å c=7.887(5)Å
α=90.00° β=90.00° γ=90.00°
N,N-dimethyl-3α,7α,12α-Trihydroxy-5β-cholan-24-amide Hemihydrate
C26H49NO5.5
Acta Crystallographica Section C (1997) 53, 3 334-339
a=16.565(3)Å b=39.504(4)Å c=7.824(8)Å
α=90.00° β=90.00° γ=90.00°
C24H39NaO5,C2H6O1
C24H39NaO5,C2H6O1
Acta Crystallographica Section C (1996) 52, 2 325-328
a=7.7383(17)Å b=15.098(2)Å c=22.515(5)Å
α=90° β=90° γ=90°
α-indomethacin
C19H16ClNO4
Journal of the American Chemical Society (2002) 124, 50 15012-15019
a=5.4616(16)Å b=25.310(9)Å c=18.152(7)Å
α=90.00° β=94.38(3)° γ=90.00°
Vitamine B1
C12H20Cl2N4O2S
Crystal Growth & Design (2003) 3, 6 997
a=6.9928(2)Å b=20.6631(10)Å c=11.7695(5)Å
α=90.00° β=98.699(2)° γ=90.00°
Vitamine B1
C12H18Cl2N4OS
Crystal Growth & Design (2003) 3, 6 997
a=7.0994(6)Å b=19.808(2)Å c=11.6378(11)Å
α=90.00° β=101.529(6)° γ=90.00°
C37H71NO15
C37H71NO15
Journal of Pharmaceutical Sciences (1997) 86, 11 1239-1244
a=9.1829(8)Å b=9.6316(7)Å c=47.151(13)Å
α=90° β=90° γ=90°